TARQOQ SKLEROZ VA NEYRODEGENERATSIYA, KOGNITIV BUZILISHLARNI BASHORAT QILISHDA BIOMARKERLARNING O‘RNI

##article.authors##

  • Yuldasheva Barno Maribjanovna ##default.groups.name.author##
  • Asqarov Elyor Sadiraliyevich ##default.groups.name.author##

##semicolon##

Tarqoq skleroz, neyrodegeneratsiya, kognitiv buzilishlar, biomarkerlar, neyrofilament yengil zanjiri.

##article.abstract##

 Ushbu maqolada tarqoq skleroz (TS)da kognitiv buzilishlarni 
bashorat qilishda biomarkerlarning diagnostik va prognostik ahamiyati yoritilgan. 
Tadqiqotda neyrofilament yengil zanjiri (NfL) va glial fibrillyar kislotali oqsil (GFAP) 
darajalari tahlil qilinib, ularning neyrodegeneratsiya va kognitiv yetishmovchilik bilan 
bog‘liqligi 
aniqlangan. 
Neyrovizualizatsiya 
ma’lumotlari 
biomarkerlar 
konsentratsiyasi bilan miya korteksining atrofiya darajasi o‘rtasidagi bog‘liqlikni 
ko‘rsatadi. Maqola TS bilan og‘rigan bemorlarda shaxsiylashtirilgan monitoring 
strategiyalarini ishlab chiqish uchun klinik amaliyotda ushbu biomarkerlarning 
ahamiyatini asoslaydi. 

##submission.citations##

1. Disanto G., Barro C., Benkert P., et al. Serum Neurofilament light: A biomarker of

neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857–870.

2. Chitnis T., Gonzalez C., Healy B.C., et al. Neurofilament light chain in blood and

cerebrospinal fluid and relapses in multiple sclerosis. JAMA Neurol. 2018;75(9):1045

1053.

3. Watanabe M., Nakamura Y., Michalak Z., et al. Glial fibrillary acidic protein is a

marker for remote astrogliosis in progressive multiple sclerosis. Brain Pathol.

2020;30(4):743–754.

4. Kuhle J., Kropshofer H., Haering D.A., et al. Blood neurofilament light chain as a

biomarker of MS disease activity and treatment response. Neurology.

2019;92(10):e1007–e1015.

5. Calabrese M., Favaretto A., Martini V., et al. Gray matter lesions and atrophy in MS:

clinical implications. Neurol Sci. 2017;38(1):23–27.

6. Yaldizli O., Penner I.K., Frontzek K., et al. The association between neurofilament

levels, cognitive function, and MRI measures in multiple sclerosis. Mult Scler J.

2020;26(10):1261–1270.

7. Lassmann H. Pathogenic mechanisms associated with different clinical courses of

multiple sclerosis. Front mmunol. 2018;9:3116.

##submissions.published##

2025-08-19